| Publisher’s Note: Join the Fierce Editors and 500+ industry leaders at Fierce JPM Week in San Francisco next week on Jan 14-15th! Spots are limited — register now! |
Today’s Big NewsJan 7, 2025 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
| By Nick Paul Taylor AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis by targeting eIF2B have taken a hit. Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on the primary endpoints. |
|
|
|
By James Waldron CytomX Therapeutics is shrinking its head count by 40% as the biotech regroups and looks at fresh ways to conserve cash. |
By James Waldron Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug. |
Sponsored by Astellas Pharma Inc. Discover how Astellas builds innovation partnerships with ambitious organizations that share their vision to transform the lives of patients |
|
Life sciences companies face the challenge of meeting today’s performance, innovation, and competitive requirements while preparing for the unknown. Access this report to learn how to adopt the right approaches to achieve true organizational transformation by leveraging a wide array of data sources alongside a digitization strategy. Download now. 
|
|
By Nick Paul Taylor Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some of its $215 million war chest to assess monthly dosing of the injectable therapy. |
By Gabrielle Masson Novo Nordisk wants to expand its legacy in metabolic conditions, inking a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations. |
By James Waldron Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925 million biobucks deal with WuXi Biologics for a preclinical candidate. |
By Gabrielle Masson Vertex Pharmaceuticals is hoping to build on its existing rare blood disorder treatment legacy, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. |
By Gabrielle Masson,Darren Incorvaia The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Darren Incorvaia Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program. |
By Darren Incorvaia Tissue biopsies can be important parts of testing new drugs, and the FDA has now issued a draft guidance with recommendations for when they should be included in clinical trial protocols. |
By Kevin Dunleavy Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival victory against AstraZeneca’s standard-of-care Tagrisso as a first-line treatment for advanced or metastatic non-small cell lung cancer. |
By Heather Landi A Louisiana patient who had been hospitalized with the first human case of highly pathogenic avian influenza, or H5N1, in Louisiana and the U.S. has died, the state's health department reported Monday. |
By Zoey Becker After its drug met the mark in a phase 3 study in essential thrombocythemia, PharmaEssentia looks to file an expansion bid with the FDA by the end of 2025. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
|
Gene therapies are growing fast, but they have one big challenge ahead: making them at a commercial scale. Access this report for an important look at the critical requirements that gene therapy manufacturers should assess when starting their custom reagent journey. Download today! 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
